• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Wednesday

    6/14/23 1:13:07 PM ET
    $AKU
    $AY
    $BENF
    $BIOC
    Medical Specialities
    Health Care
    Electric Utilities: Central
    Utilities
    Get the next $AKU alert in real time by email

     

    On Wednesday, 33 stocks hit new 52-week lows.

    Interesting Facts About Today's 52-Week Lows:

    • The largest company by market cap to set a new 52-week low was UnitedHealth Group (NYSE:UNH).
    • Biocept (NASDAQ:BIOC) was the smallest, in terms of market cap, to set a new 52-week low.
    • Tenon Medical (NASDAQ:TNON) shares traded down 51.96% to reach its 52-week low, making it the biggest loser.
    • Camber Energy (AMEX:CEI) shares actually gained 0.16%, rebounding after it reached its 52-week low.

    The stocks that set new 52-week lows on Wednesday:

    • UnitedHealth Group (NYSE:UNH) stock dropped to a yearly low on Wednesday of $445.83. Shares traded down 7.25%.
    • Atlantica Sustainable (NASDAQ:AY) stock drifted down 1.08% on Wednesday morning to hit a new 52-week low of $23.70.
    • Beneficient (NASDAQ:BENF) stock set a new 52-week low of $5.21 on Wednesday, moving down 7.19%.
    • PolyMet Mining (AMEX:PLM) shares hit a yearly low of $0.82. The stock was up 0.22% on the session.
    • Intevac (NASDAQ:IVAC) stock drifted down 13.84% on Wednesday morning to hit a new 52-week low of $3.68.
    • Precision BioSciences (NASDAQ:DTIL) shares hit a yearly low of $0.66. The stock was down 3.52% on the session.
    • Mullen Automotive (NASDAQ:MULN) shares made a new 52-week low of $0.27 on Wednesday. The stock was down 12.88% for the day.
    • FLJ Group (NASDAQ:FLJ) shares hit a yearly low of $0.28. The stock was down 13.73% on the session.
    • Great Elm Capital (NASDAQ:GECC) shares made a new 52-week low of $7.55 on Wednesday. The stock was down 3.5% for the day.
    • Passage Bio (NASDAQ:PASG) shares set a new 52-week low of $0.93. The stock traded down 0.75%.
    • IO Biotech (NASDAQ:IOBT) shares hit a yearly low of $1.58. The stock was down 19.66% on the session.
    • Upexi (NASDAQ:UPXI) shares set a new yearly low of $2.04 this morning. The stock was down 6.74% on the session.
    • Trio Petroleum (AMEX:TPET) stock hit $1.30 on Wednesday morning, setting a new 52-week low for a change of down 2.96%.
    • Akumin (NASDAQ:AKU) shares reached a new 52-week low of $0.33 on Wednesday morning, moving up 2.19%.
    • Castellum (AMEX:CTM) shares fell to $0.56 on Wednesday, setting a new 52-week low with a shift of down 4.72%.
    • Camber Energy (AMEX:CEI) stock hit a new 52-week low of $1.00. The stock was up 0.16% on the session.
    • iClick Interactive Asia (NASDAQ:ICLK) stock hit $2.05 on Wednesday morning, setting a new 52-week low for a change of down 4.66%.
    • Cineverse (NASDAQ:CNVS) stock hit $2.20 on Wednesday morning, setting a new 52-week low for a change of down 35.53%.
    • SMX (Security Matters) (NASDAQ:SMX) shares fell to $0.62 on Wednesday, setting a new 52-week low with a shift of down 17.84%.
    • Bluejay Diagnostics (NASDAQ:BJDX) stock hit a yearly low of $0.19. The stock was down 4.55% for the day.
    • OceanPal (NASDAQ:OP) shares reached a new 52-week low of $2.53 on Wednesday morning, moving down 7.66%.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares set a new yearly low of $0.59 this morning. The stock was up 1.37% on the session.
    • INVO Bioscience (NASDAQ:INVO) stock hit a yearly low of $0.15. The stock was down 5.27% for the day.
    • Biocept (NASDAQ:BIOC) stock set a new 52-week low of $1.64 on Wednesday, moving down 2.58%.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $AKU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKU
    $AY
    $BENF
    $BIOC

    CompanyDatePrice TargetRatingAnalyst
    Cineverse Corp.
    $CNVS
    2/19/2026$12.00Speculative Buy → Buy
    The Benchmark Company
    Passage Bio Inc.
    $PASG
    2/10/2026$21.00Buy
    Chardan Capital Markets
    IO Biotech Inc.
    $IOBT
    1/26/2026$0.50Overweight → Neutral
    Piper Sandler
    IO Biotech Inc.
    $IOBT
    1/8/2026$0.36Equal-Weight → Underweight
    Morgan Stanley
    UnitedHealth Group Incorporated
    $UNH
    10/29/2025$333.00Buy → Hold
    Deutsche Bank
    UnitedHealth Group Incorporated
    $UNH
    10/14/2025$406.00Buy
    Goldman
    IO Biotech Inc.
    $IOBT
    9/30/2025$0.39Overweight → Equal-Weight
    Morgan Stanley
    IO Biotech Inc.
    $IOBT
    9/30/2025Buy → Hold
    TD Cowen
    More analyst ratings

    $AKU
    $AY
    $BENF
    $BIOC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres Tech/Chief Product Off Huidor Mark Antonio bought $75,000 worth of shares (37,500 units at $2.00), increasing direct ownership by 25% to 190,061 units (SEC Form 4)

    4 - Cineverse Corp. (0001173204) (Issuer)

    2/17/26 9:57:19 PM ET
    $CNVS
    Consumer Electronics/Video Chains
    Consumer Discretionary

    CFO Lindsey Mark Wayne bought $70,000 worth of shares (35,000 units at $2.00), increasing direct ownership by 29% to 154,168 units (SEC Form 4)

    4 - Cineverse Corp. (0001173204) (Issuer)

    2/17/26 9:54:43 PM ET
    $CNVS
    Consumer Electronics/Video Chains
    Consumer Discretionary

    Chief Motion Pictures Officer Macias Yolanda sold $5,297 worth of shares (2,189 units at $2.42) and bought $60,000 worth of shares (30,000 units at $2.00), increasing direct ownership by 30% to 121,760 units (SEC Form 4)

    4 - Cineverse Corp. (0001173204) (Issuer)

    2/17/26 9:54:04 PM ET
    $CNVS
    Consumer Electronics/Video Chains
    Consumer Discretionary

    $AKU
    $AY
    $BENF
    $BIOC
    SEC Filings

    View All

    Passage Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Passage BIO, Inc. (0001787297) (Filer)

    3/10/26 7:15:33 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Trio Petroleum Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Trio Petroleum Corp (0001898766) (Filer)

    3/10/26 6:08:25 AM ET
    $TPET
    Oil & Gas Production
    Energy

    SEC Form 424B5 filed by Trio Petroleum Corp.

    424B5 - Trio Petroleum Corp (0001898766) (Filer)

    3/10/26 6:03:56 AM ET
    $TPET
    Oil & Gas Production
    Energy

    $AKU
    $AY
    $BENF
    $BIOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Williamson Kevin converted options into 1,041 shares, increasing direct ownership by 2% to 43,593 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    3/5/26 4:37:46 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    New insider Reese Jason W. claimed ownership of 316,697 shares (SEC Form 3)

    3 - Great Elm Capital Corp. (0001675033) (Issuer)

    3/5/26 4:15:17 PM ET
    $GECC
    Finance: Consumer Services
    Finance

    Chief Accounting Officer Roos Thomas E covered exercise/tax liability with 152 shares and was granted 2,436 shares, increasing direct ownership by 8% to 31,284 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    2/25/26 4:11:27 PM ET
    $UNH
    Medical Specialities
    Health Care

    $AKU
    $AY
    $BENF
    $BIOC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

    – Findings reinforce differentiated in vivo gene editing approach designed for durable functional muscle improvement through satellite cell editing – – PBGENE-DMD treatment in a humanized DMD mouse model demonstrates improvements in muscle pathology and biomarkers of muscle damage – – PBGENE-DMD shows durable dystrophin protein restoration in humanized DMD mice across key muscle groups, including cardiac, diaphragm, and skeletal muscles – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced presentation of new preclinical s

    3/10/26 7:01:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases

    3/9/26 4:15:00 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

    – Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy – – March 17, 2026 virtual webinar to feature expert insights on potential clinical utility of PBGENE-DMD for patients with Duchenne muscular dystrophy and the planned Phase 1/2 FUNCTION-DMD clinical study – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for th

    3/9/26 7:01:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $AY
    $BENF
    $BIOC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cineverse upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Cineverse from Speculative Buy to Buy and set a new price target of $12.00

    2/19/26 7:46:51 AM ET
    $CNVS
    Consumer Electronics/Video Chains
    Consumer Discretionary

    Chardan Capital Markets resumed coverage on Passage BIO with a new price target

    Chardan Capital Markets resumed coverage of Passage BIO with a rating of Buy and set a new price target of $21.00

    2/10/26 6:56:48 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IO Biotech downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded IO Biotech from Overweight to Neutral and set a new price target of $0.50

    1/26/26 10:01:23 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKU
    $AY
    $BENF
    $BIOC
    Leadership Updates

    Live Leadership Updates

    View All

    Efinix Appoints Cameron McAulay as Chief Financial Officer

    McAulay Brings a Decade of Public-Company Semiconductor CFO Experience to Support Efinix's Global Expansion Efinix, Inc., the FPGA pioneer accelerating edge AI innovation, today announced the appointment of Cameron McAulay as Chief Financial Officer and Senior Vice President Finance. McAulay brings more than 20 years of financial leadership experience in the semiconductor and technology industries, including over a decade of service as CFO at publicly traded companies, making him uniquely qualified to help guide Efinix through its next stage of growth and value creation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303081

    3/3/26 11:00:00 AM ET
    $IVAC
    $TGAN
    Industrial Machinery/Components
    Technology
    Semiconductors

    Cineverse and GameStop Invite Fans to 'Return to Silent Hill' with Innovative Partnership featuring Mysterious Messages, Exclusive Rewards, In-Store Media & More

    Return to Silent Hill Hits Theaters Nationwide on January 23 – Buy Tickets Now LOS ANGELES and GRAPEVINE, Texas, Jan. 14, 2026 /PRNewswire/ -- Cineverse (NASDAQ:CNVS), a next generation entertainment studio, and GameStop Corp. (NYSE:GME), are pulling out all the stops in anticipation of the January 23 wide theatrical release of Return to Silent Hill (returntosilenthillmovie.com).  The two companies are collaborating on an immersive marketing campaign for the new film, based on the visionary video game, SILENT HILL 2. Since January 7, fans who visit a participating GameStop ca

    1/14/26 3:02:00 PM ET
    $CNVS
    $GME
    Consumer Electronics/Video Chains
    Consumer Discretionary
    Electronics Distribution

    Beneficient Appoints Peter T. Cangany Jr. as Chairman of the Board

    DALLAS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF) ("Ben" or the "Company"), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that its Board of Directors (the "Board") has appointed Peter T. Cangany Jr. as Chairman of the Board, effective December 15, 2025. Mr. Cangany has served as a director of Beneficient and as Chairman of its independent Audit Committee since 2019. He brings decades of leadership experience in financial reporting, accounting, and corporate governance within the financial services industry. Mr. Cangany retired as a partner

    12/17/25 7:30:00 AM ET
    $BENF
    Finance: Consumer Services
    Finance

    $AKU
    $AY
    $BENF
    $BIOC
    Financials

    Live finance-specific insights

    View All

    Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases

    3/9/26 4:15:00 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Great Elm Capital Corp. Announces Fourth Quarter and Full Year 2025 Financial Results and New Executive Chairman of Board

    Company to Host Conference Call and Webcast at 8:30 AM ET on March 3, 2026 Jason Reese Appointed as Executive Chairman of the Board of Directors, Succeeding Matthew Drapkin and Fortifying the Board's Management Oversight Mr. Drapkin Continues to Serve as Vice Chairman of Great Elm Group, Inc. - Remaining Engaged with GECC and Great Elm Capital Management, LLC, its Investment Adviser Platform Strengthened with Seasoned Credit Investor Chris Croteau Hired as Head of Research GECC's Investment Adviser Waives All Accrued Incentive Fees as of December 31, 2025, Equating to Approximately $2.3 Million, or $0.16 Per Share, and 1Q 2026 Incentive Fees Waived as Well GAAP NAV of $8.07 Per Share a

    3/2/26 5:47:04 PM ET
    $GECC
    $GEG
    Finance: Consumer Services
    Finance
    Computer Software: Prepackaged Software
    Technology

    Great Elm Capital Corp. ("GECC") Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    PALM BEACH GARDENS, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Great Elm Capital Corp. (the "Company" or "GECC") (NASDAQ:GECC), a business development company, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, after the close of market trading on Monday, March 2, 2026. The results will be discussed in a conference call on Tuesday, March 3, 2026, at 8:30 a.m. ET. Date/Time:Tuesday, March 3, 2026 – 8:30 a.m. ET   Participant Dial-In Numbers: (United States):(877) 407-0789(International):(201) 689-8562   To access the call, please dial-in approximately five minutes before the start time and, when asked, provide the operator w

    2/27/26 4:22:51 PM ET
    $GECC
    Finance: Consumer Services
    Finance

    $AKU
    $AY
    $BENF
    $BIOC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Great Elm Capital Corp.

    SC 13D/A - Great Elm Capital Corp. (0001675033) (Subject)

    12/13/24 6:47:34 PM ET
    $GECC
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13D/A filed by Atlantica Sustainable Infrastructure plc

    SC 13D/A - Atlantica Sustainable Infrastructure plc (0001601072) (Subject)

    12/12/24 12:30:42 PM ET
    $AY
    Electric Utilities: Central
    Utilities

    SEC Form SC 13G filed by Great Elm Capital Corp.

    SC 13G - Great Elm Capital Corp. (0001675033) (Subject)

    12/12/24 8:44:54 AM ET
    $GECC
    Finance: Consumer Services
    Finance